Former drug company executive Martin Shkreli is convicted of fraud

NEW YORK, Aug 4 (Reuters) - Former drug company executive Martin Shkreli was convicted of securities fraud by jurors in a U.S. court in Brooklyn on Friday, after a highly publicized, monthlong trial.

Federal prosecutors had accused the 34-year-old of defrauding investors in his hedge funds and stealing from his old drug company, Retrophin Inc, to pay them back.

Jurors found Shkreli guilty on two counts of securities fraud and one count of conspiracy, on the fifth day of deliberations. Shkreli was also found not guilty on five other conspiracy counts.

RELATED: Martin Shkreli's outrageous faces during congressional hearing, Turing Pharmaceutical

Before going on trial, Shkreli had been best known for raising the price of anti-infection drug Daraprim by 5,000 percent in 2015 as chief executive of Turing Pharmaceuticals.

That increase sparked outrage from U.S. lawmakers and patients, and earned Shkreli the nickname "Pharma bro."

The charges stemmed from his career before Turing, as chief executive of Retrophin and manager of hedge funds MSMB Capital and MSMB Healthcare.

Prosecutors claimed that between 2009 and 2014, he lied to MSMB investors, lost their money and paid them back with cash and stock misappropriated from Retrophin.

Jurors heard testimony from several MSMB investors who said Shkreli falsely claimed to have an outside auditor and tens of millions of dollars in assets, sent them fabricated account statements after losing their money and became evasive when they asked for their investments back.

RELATED: Former drug company executive Martin Shkreli

Prosecutors said Shkreli eventually paid investors back with stock or cash from Retrophin by having them sign settlement or consulting agreements with the company. Retrophin directors testified that they did not approve those agreements in advance.

Shkreli's lawyer, Benjamin Brafman, had urged jurors to see his client not as a fraudster but as an eccentric genius determined to find cures for rare diseases.

Brafman said that while Shkreli's statements to investors were not always true, he made them in good faith. He also emphasized that none of Shkreli's investors lost money, a rarity in a securities fraud case. (Reporting By Brendan Pierson in New York; Editing by Jonathan Oatis)